Targets › SLC6A3
48 programs from 44 companies in 100 trials: 38 Phase 2, 29 Phase 4, 19 Phase 3, 14 Phase 1; Psychiatry, Other, Metabolic and endocrine; next expected readout Nov 2026.
Mediates sodium- and chloride-dependent transport of dopamine. Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). (UniProt, Q01959)
Open in Phaseline: the race on SLC6A3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Primus Pharmaceuticals | Metaxalone 640 mg Skeletal muscle relaxant | SLC6A3 | Phase 4 | Sciatica Acute; Healthy Participants | Nov 2026 |
| Rochester Center for Behavioral Medicine | Dyanavel XR Amphetamine derivative; CNS stimulant that increases dopamine and norepinephrine release | SLC6A2, SLC6A3 | Phase 4 | Fatigue | Dec 2026 |
| Daniel Coury | Amphetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent | SLC6A3, SLC6A2 | Phase 4 | ADHD | Jan 2027 |
| Daniel Coury | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | ADHD | Jan 2027 |
| Matthew J O'Brien, PhD, BCBA-D | Amphetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder | Mar 2027 |
| Donald Gilbert, MD, MS, FAAN, FAAP | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder Combined | Mar 2027 |
| VA Office of Research and Development | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Posttraumatic Stress Disorder (PTSD); Epilepsy | Mar 2027 |
| Columbia University | Naltrexone-Bupropion Combination Opioid receptor antagonist (naltrexone) combined with norepinephrine-dopamine reuptake inh | OPRM1, SLC6A3 | Phase 4 | Obesity | Jun 2027 |
| Dar Clinical Research Inc. | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder | Jul 2027 |
| The Chaim Sheba Medical Center | methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Velocardiofacial Syndrome | Aug 2027 |
| Axsome Therapeutics | Bupropion (AXS-05) Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Major Depressive Disorder; Smoking Cessation; Major Depressive Disorder (MDD); Cigarette Smoking-Related Carcinoma … | Dec 2027 |
| Johns Hopkins University | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | ADHD - Combined Type | Nov 2028 |
| Currax Pharmaceuticals | Bupropion Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Obesity | Jan 2029 |
| Gagan Joshi | Amphetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Hyperactivity Disorder (ADHD) | Feb 2030 |
| Children's Hospital Medical Center, Cincinnati | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Feb 2030 |
| Hospital de Clinicas de Porto Alegre | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention Deficit Disorder With Hyperactivity | Dec 2032 |
| The Royal's Institute of Mental Health Research | Contrave Naltrexone/Bupropion combination; naltrexone is a mu-opioid receptor antagonist and buprop | OPRM1, SLC6A2, SLC6A3 | Phase 4 | Obesity | – |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Flupentixol-Melitracen Antipsychotic-antidepressant combination; flupentixol is a dopamine antagonist, melitracen | DRD2, SLC6A3 | Phase 4 | Thyroid-Associated Ophthalmopathy | – |
| NYU Langone Health | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | Attention-deficit/Hyperactivity Disorder | – |
| Florida International University | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 4 | ADHD | – |
| Iuliu Hatieganu University of Medicine and Pharmacy | Nefopam Non-opioid analgesic; mechanism includes monoamine reuptake inhibition and NMDA receptor a | SLC6A2, SLC6A3, GRIN1 | Phase 4 | Pancreatoduodenectomy | – |
| Axsome Therapeutics | Solriamfetol Dose A Dopamine and norepinephrine reuptake inhibitor | SLC6A3, SLC6A2 | Phase 3 | Excessive Sleepiness; Binge-Eating Disorder; ADHD; Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Dec 2026 |
| M.D. Anderson Cancer Center | Methylphenidate Hydrochloride Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Advanced Malignant Neoplasm; Sleep; Prostate Cancer; Prostate Carcinoma … | Dec 2026 |
| University Hospital, Strasbourg, France | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Adult ADHD | May 2027 |
| Otsuka | Centanafadine (EB-1020) Monoamine transporter inhibitor | SLC6A4, SLC6A3, SLC6A2 | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD) | Aug 2027 |
| Odense University Hospital | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Brain Tumor, Pediatric | Dec 2029 |
| Vrije Universiteit Brussel | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 3 | Fatigue | – |
| University of Haifa | methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Posttraumatic Stress Disorder; PTSD | Dec 2026 |
| Remedy | Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Post Traumatic Stress Disorder | Mar 2027 |
| Definium Therapeutics US | Midomafetamine (DT402) Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Autism Spectrum Disorder | Aug 2027 |
| Institut National de la Santé Et de la Recherche Médicale, France | 18F-LBT-999 Dopamine transporter (DAT) PET imaging agent | SLC6A3 | Phase 2 | Coma, Traumatic | Sep 2027 |
| Sunnybrook Health Sciences Centre | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Alzheimer s Disease | Oct 2027 |
| Medical University of Lodz | Lisdexamfetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor | SLC6A3, SLC6A2, SLC18A2 | Phase 2 | Attention Deficit Disorder with Hyperactivity | Dec 2027 |
| Medical University of Lodz | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Attention Deficit Disorder with Hyperactivity | Dec 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Lisdexamfetamine Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor | SLC6A3, SLC6A2, SLC18A2 | Phase 2 | Methamphetamine Abuse | Dec 2027 |
| University of Rochester | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 2 | Chronic Pain | Dec 2027 |
| Prof. Dr. Frank Behrens | DEX IR tablets Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin | SLC6A3, SLC6A2 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Mar 2028 |
| Prof. Dr. Frank Behrens | DEX XL Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin | SLC6A3, SLC6A2 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Mar 2028 |
| Gradalis | Modafinil Dopamine transporter inhibitor | SLC6A3 | Phase 2 | Ovarian Cancer; Sleep Deprivation; Attention - no Condition is Being Assessed - Healthy Adults; Cognition … | Dec 2028 |
| Parnassia Addiction Research Centre | Sustained-release Dexamphetamine Dopamine reuptake inhibitor | SLC6A3 | Phase 2 | Cocaine Use Disorder | Jan 2029 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 18F-DOPA Dopamine transporter imaging agent for neuroendocrine tumors | SLC6A3 | Phase 2 | ACTH | Dec 2030 |
| AlgoTherapeutix | ATX01 10% Amitriptyline hydrochloride topical formulation; tricyclic antidepressant with analgesic p | SLC6A4, SLC6A3 | Phase 2 | Chemotherapy-induced Peripheral Neuropathy | – |
| CSPC ZhongQi Pharmaceutical Technology | Ammoxetine hydrochloride Enteric-coated Tablets (new formulation) norepinephrine-dopamine reuptake inhibitor | SLC6A3 | Phase 1 | Healthy Participants | Nov 2026 |
| Resilient Pharmaceuticals | Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 1 | Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder … | Feb 2027 |
| St. Jude Children's Research Hospital | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 1 | Sickle Cell Disease | Jul 2027 |
| Rachel Yehuda | MDMA Hydrochloride Serotonin-norepinephrine-dopamine releasing agent; promotes prosocial behavior and emotion | SLC6A4, SLC6A2, SLC6A3 | Phase 1 | Mental Wellbeing | Sep 2029 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | [18F]-DOPA Fluorine-18 labeled L-DOPA for neuroendocrine tumor imaging via amino acid uptake and deca | SLC6A3 | Phase 1 | Pheochromocytoma | Nov 2048 |
| Massachusetts General Hospital | Methylphenidate Dopamine transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A3, SLC6A2 | Phase 1 | Brain Injury Traumatic Severe (Diagnosis) | – |
Post Traumatic Stress Disorder (6) Healthy Participants (5) ADHD (5) Obesity (3) Attention Deficit Hyperactivity Disorder (ADHD) (3) Posttraumatic Stress Disorder (3) Attention-Deficit/Hyperactivity Disorder (ADHD) (3) Schizophrenia (3) Attention Deficit Hyperactivity Disorder (2) Attention-Deficit Hyperactivity Disorder(ADHD) (2) PTSD (2) Attention Deficit Disorder with Hyperactivity (2)
small molecule (39), protein or peptide (6), mixed (2), antibody (1)
Axsome Therapeutics (2) Medical University of Lodz (2) Daniel Coury (2) Prof. Dr. Frank Behrens (2) Columbia University (1) CSPC ZhongQi Pharmaceutical Technology (1) Johns Hopkins University (1) Rachel Yehuda (1) NYU Langone Health (1) Donald Gilbert, MD, MS, FAAN, FAAP (1) Iuliu Hatieganu University of Medicine and Pharmacy (1) The Chaim Sheba Medical Center (1) University of Rochester (1) Dar Clinical Research Inc. (1) M.D. Anderson Cancer Center (1) Currax Pharmaceuticals (1) Otsuka (1) Primus Pharmaceuticals (1) VA Office of Research and Development (1) University of Haifa (1)
SLC6A2 (38) SLC6A4 (6) OPRM1 (2) SLC18A2 (2) GRIN1 (1) DRD2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.